Show simple item record

dc.contributor.authorZhang, Fuming
dc.contributor.authorSun, Peilong
dc.contributor.authorMunoz, Eva
dc.contributor.authorChi, Lianli
dc.contributor.authorSakai, Shinobu
dc.contributor.authorToida, Toshihiko
dc.contributor.authorZhang, Haifeng
dc.contributor.authorMousa, Shaker
dc.contributor.authorLinhardt, Robert J.
dc.date2006
dc.date.accessioned2022-06-23T03:56:09Z
dc.date.available2022-06-23T03:56:09Z
dc.date.issued2006-06-15
dc.identifier.citationMicroscale Isolation and Analysis of Heparin from Plasma using an Anion Exchange Spin Column, F. Zhang, P. Sun, E. Mu“oz, L.Chi, S. Sakai, T. Toida, H. Zhang, S. Mousa R. J. Linhardt, Analytical Biochemistry, 353, 284–286, 2006.
dc.identifier.issn10960309
dc.identifier.issn32697
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5178
dc.identifier.urihttps://doi.org/10.1016/j.ab.2006.01.040
dc.descriptionAnalytical Biochemistry, 353, 284–286
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractHeparin, a linear highly sulfated polysaccharide, is a member of the glycosaminoglycan (GAG)1 family [1,2]. Since the 1930s, heparin has been widely used as a clinical anticoagulant [3,4]. More recently, low-molecular weight heparin (LMWH) derivatives have come into widespread use as anticoagulant and antithrombotic drugs [5]. Although heparin’s clinical use predated the establishment of the US. Food and Drug Administration (FDA), the approval of LMWH required a number of pharmacological studies on these new drugs. The pharmacologically relevant concentration of heparin and LMWH in plasma is between 0.1 and 1.0 anti-factor XaU/ml, corresponding to approximately 1–10 µg/ml of drug [6]. Plasma is a complex mixture, making the direct analysis of heparin or LMWH at these concentrations exceedingly challenging. Thus, most of the pharmacological studies of heparin and LMWH have relied on bioassays such as anti-factor Xa activity to evaluate these agents, providing only pharmacodynamic data. This inability to obtain pharmacokinetic data on LMWH is a serious concern because the plasma anti-factor Xa activity of LMWH does not correlate well with its therapeutic efficacy [7].
dc.description.sponsorshipNational Institutes of Health
dc.languageen_US
dc.language.isoENG
dc.publisherElsevier
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofAnalytical Biochemistry
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleMicroscale Isolation and Analysis of Heparin from Plasma using an Anion Exchange Spin Column
dc.typeArticle
dcterms.accessRightsA full text version is available in DSpace@RPI
dcterms.isPartOfJournal
dcterms.isVersionOfhttps://doi.org/10.1016/j.ab.2006.01.040
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
rpi.description.pages284-286
rpi.description.volume353


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record